Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05304468
PHASE3

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Sponsor: Sun Yat-sen University

View on ClinicalTrials.gov

Summary

To study the 2-year PFS (progression-free survival) of patients with stage II-III nasopharyngeal carcinoma treated with induction chemotherapy followed by two different doses of intensity modulated radiation therapy plus concurrent cisplatin chemotherapy

Official title: Phase III Randomized Non-inferiority Trial of Reduced-dose Versus Standard Dose Radiotherapy for Stage II-III Nasopharyngeal Carcinoma Which Have Favorable Response After Induction Chemotherapy

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

452

Start Date

2022-05-11

Completion Date

2029-10-29

Last Updated

2025-03-21

Healthy Volunteers

No

Interventions

RADIATION

IMRT

Patients in experimental group received reduced dose IMRT

DRUG

induction chemotherapy

cisplatin-based induction chemotherapy for two cycles

DRUG

cisplatin concurrent chemotherapy

cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)

Locations (1)

Sun Yat-sen Universitty Cancer Center

Guangzhou, Guangdong, China